Your search for ‘Patterson Belknap Webb & Tyler LLP’ returned 579 results

This alert summarizes two important provisions that were recently added to the Family and Medical Leave Act (FMLA) regarding the type and scope of leave available to families of military servicemembers.

We have blogged previously about section 546(e), the Bankruptcy Code's safe harbor for certain transfers otherwise subject to avoidance as preferences or fraudulent transfers.

The decision is consistent with themes that the Justices had raised during oral argument on March 31, 2015.

The Internal Revenue Service in July 2007 issued new, comprehensive regulations under Internal Revenue Code Section 403(b).

On Friday the Solicitor General filed an amicus brief in Kimble v. Marvel Enterprises.

On Friday, the Federal Circuit issued its highly anticipated decision in Association for Molecular Pathology, et al. v. Myriad Genetics.

The recently enacted American Recovery and Reinvestment Act of 2009 (the "Stimulus Act") includes a number of new tax breaks, both large and small, and extends several existing tax breaks for businesses and individuals.

Today the FDA announced the first approval of a biosimilar product in the United States under the Biologics Price Competition and Innovation Act (BPCIA).

As readers may be aware, a qualified retirement plan or a Section 403(b) retirement plan is generally required to report information about separated participants with deferred vested benefits under the plan.

We previously alerted you to proposed legislation affecting New York estate tax law.

As we have alerted you in the past, health care reform enacted in 2010 under the Patient Protection and Affordable Care Act has imposed new obligations on employers and group health plans.

IRS regulations regarding Section 409A of the Internal Revenue Code will become effective on January 1, 2009.

Earlier this month, the FDA approved the biosimilar Zarxio (filgrastim-sndz) for sale in the United States.

The FDA Approved Label For The First U.S. Biosimilar, Sandoz's Zarxio, Has Raised Concerns.

Drug company Turing Pharmaceuticals made headlines recently when it reportedly raised the price of Daraprim, used commonly by AIDS patients to fight life-threatening infections, from $13.50 to $750 per tablet.

As the country’s largest health insurer, Medicare has immense influence on the health care market.

Recognizing that the requirement to have a detailed written plan document for a 403(b) retirement plan was a new and arduous task for many non-profit entities who sponsored such plans, the IRS has now published favorable guidance giving 403(b) retirement plan sponsors some much needed relief.

Recent guidance from the IRS modifies the long-standing "use or lose it" rule under a health flexible spending arrangement ("Health FSA") to permit such arrangements to offer participants the opportunity to carryover up to $500 in unused Health FSA benefits for a plan year to the following plan year for reimbursement of medical care expenses incurred in such subsequent year.